Jasper Therapeutics 471CVR019 深 滬
等待開盤 11-05 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 --
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock effective November 6, 2026. The stock will trade on a split-adjusted basis under the symbol "JSPR" with a new CUSIP number. Each 30 shares will convert to 1 share, with cash paid for fractional shares. The reverse split aims to help the company regain compliance with Nasdaq listing requirements.
11-04 13:00
William Blair Reinstates Outperform on Jasper Therapeutics
William Blair analyst Matt Phipps reinstates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform.
10-15 02:51
Jasper Therapeutics Launches Tender Offer to Retire Warrants
Jasper Therapeutics ( ($JSPR) ) has issued an update. On October 7, 2026, Jaspe...
10-07 20:28
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics, Inc. has commenced an offer to purchase all outstanding warrants issued in its September 2025 public offering at a price of $0.324 per warrant. The purpose is to reduce potential dilution and provide clarity on the company's capital structure. The offer will expire on November 6, 2026, with un-tendered warrants expiring on March 18, 2030. Jasper is a clinical-stage biotech company developing therapies for immune-mediated dise...
10-07 12:00
Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the "Company") in order to pursue other professional endeavors. ...
09-29 04:48
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, in New York. Management will engage in a fireside chat, which will be live-streamed and archived on the company's website. Jasper, a clinical-stage biotech company, is developing innovative therapies for immune-mediated diseases, including KP-104, briquilimab, and KP-701.
09-09 12:00
